Bromocriptin

Phase 3Small molecule

UUniversity Hospital, Bonn

Bromocriptin is one of 10 small molecule programs targeting Hyperprolactinemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperprolactinemiaActive, not recruiting

HyperprolactinemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Hyperprolactinemia

#DrugCompanyPhaseTrials

Dostinex

Pfizer

Approved

1 2

Abilify

KKorea Otsuka Pharmaceutical Co., Ltd.

Approved

1 3

Requip Xl

GGlaxo Dba Glaxosmithkline

Phase 2

1 4

Kisspeptin

MMassachusetts General Hospital

Phase 2

1 5

Gnrh

MMassachusetts General Hospital

Phase 2

1 6

Bromocriptin

UUniversity Hospital, Bonn

Phase 3

1 7

Aimovig

Emgality

Ajovy

Abilify

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperprolactinemia1 trial

Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine

Unknown status·UUniversity Hospital, Bonn·Phase 3·NCT00315081·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bromocriptin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bromocriptin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bromocriptin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bonn company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Bonn

Bromocriptin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperprolactinemia1 trial

References

Drug Info

Quick Facts

Related News